公开(公告)号：DE60130799D1

公开(公告)日：2007-11-15

申请号：DE60130799

申请日：2001-11-30

Applicant: CHILDRENS MEDICAL CENTER

Inventor： TRESTON ANTHONY ,  SHAH JAMSHED H ,  D AMATO ROBERT J ,  HUNSUCKER KIMBERLY A ,  ROUGAS JOHN ,  CONNER BARRY P ,  PRIBLUDA VICTOR ,  SWARTZ GLENN M

IPC: A61K31/445 ,  C07D401/04 ,  A61K31/454 ,  A61P1/16 ,  A61P1/18 ,  A61P3/02 ,  A61P3/10 ,  A61P5/00 ,  A61P7/00 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P13/08 ,  A61P15/00 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/04 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P27/06 ,  A61P27/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P31/22 ,  A61P33/00 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61P37/02

公开(公告)号：HK1083064A1

公开(公告)日：2006-06-23

申请号：HK06104412

申请日：2000-06-14

Applicant: CHILDRENS MEDICAL CENTER

Inventor： D AMATO ROBERT J

IPC: A61K20060101 ,  C07D491/044 ,  A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K31/185 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/196 ,  A61K31/20 ,  A61K31/395 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/405 ,  A61K31/4152 ,  A61K31/4164 ,  A61K31/425 ,  A61K31/44 ,  A61K31/445 ,  A61K31/45 ,  A61K31/454 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K31/621 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P19/02 ,  A61P19/06 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  C07D207/416 ,  C07D211/88 ,  C07D401/04

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

公开(公告)号：CA2270887C

公开(公告)日：2006-03-21

申请号：CA2270887

申请日：1997-11-04

Applicant: CHILDRENS MEDICAL CENTER

Inventor： D AMATO ROBERT J

IPC: A61K31/60 ,  C07D491/044 ,  A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K31/185 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/196 ,  A61K31/20 ,  A61K31/33 ,  A61K31/395 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/405 ,  A61K31/4152 ,  A61K31/4164 ,  A61K31/425 ,  A61K31/44 ,  A61K31/445 ,  A61K31/45 ,  A61K31/454 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/56 ,  A61K31/573 ,  A61K31/621 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P19/02 ,  A61P19/06 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  C07D207/416 ,  C07D211/88 ,  C07D401/04

Abstract: The present invention comprises a group of compounds that effectively inhibi t angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

公开(公告)号：AT305301T

公开(公告)日：2005-10-15

申请号：AT97946884

申请日：1997-11-04

Applicant: CHILDRENS MEDICAL CENTER

Inventor： D AMATO ROBERT J

IPC: C07D491/044 ,  A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K31/185 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/196 ,  A61K31/20 ,  A61K31/395 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/405 ,  A61K31/4152 ,  A61K31/4164 ,  A61K31/425 ,  A61K31/44 ,  A61K31/445 ,  A61K31/45 ,  A61K31/454 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K31/621 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P19/02 ,  A61P19/06 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  C07D207/416 ,  C07D211/88 ,  C07D401/04 ,  A61K31/62

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

公开(公告)号：AU5197398A

公开(公告)日：1998-05-29

申请号：AU5197398

申请日：1997-11-04

Applicant: CHILDRENS MEDICAL CENTER

Inventor： D AMATO ROBERT J

IPC: C07D491/044 ,  A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K31/185 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/196 ,  A61K31/20 ,  A61K31/395 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/405 ,  A61K31/4152 ,  A61K31/4164 ,  A61K31/425 ,  A61K31/44 ,  A61K31/445 ,  A61K31/45 ,  A61K31/454 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K31/621 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P19/02 ,  A61P19/06 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  C07D207/416 ,  C07D211/88 ,  C07D401/04

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

公开(公告)号：EP1353672A4

公开(公告)日：2004-12-15

申请号：EP01270117

申请日：2001-11-30

Applicant: CHILDRENS MEDICAL CENTER

Inventor： TRESTON ANTHONY ,  SHAH JAMSHED H ,  D AMATO ROBERT J ,  HUNSUCKER KIMBERLY A ,  ROUGAS JOHN ,  CONNER BARRY P ,  PRIBLUDA VICTOR ,  SWARTZ GLENN M

IPC: C07D401/04 ,  A61K31/454 ,  A61P1/16 ,  A61P1/18 ,  A61P3/02 ,  A61P3/10 ,  A61P5/00 ,  A61P7/00 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P13/08 ,  A61P15/00 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/04 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P27/06 ,  A61P27/10 ,  A61P29/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P31/22 ,  A61P33/00 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61P37/02 ,  A61K31/445

CPC classification number: C07D401/04 ,  A61K31/454

Abstract: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, alone or in combination with a second active agent and/or surgery.

公开(公告)号：ES2358687T3

公开(公告)日：2011-05-12

申请号：ES07121971

申请日：1997-11-04

Applicant: CHILDRENS MEDICAL CENTER

Inventor： D AMATO ROBERT J

IPC: A61K31/44 ,  A61K31/185 ,  A61K31/20 ,  A61K31/40 ,  A61K31/56 ,  A61K31/60 ,  A61P43/00

Abstract: Talidomida y dexametasona para usar en el tratamiento de un tumor transportado por la sangre, donde la talidomida y dexametasona se administran a un humano o animal conjuntamente.

公开(公告)号：DK1586322T3

公开(公告)日：2008-12-01

申请号：DK05014759

申请日：1997-11-04

Applicant: CHILDRENS MEDICAL CENTER

Inventor： D AMATO ROBERT J

IPC: A61K31/454 ,  C07D491/044 ,  A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K31/185 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/196 ,  A61K31/20 ,  A61K31/395 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/405 ,  A61K31/4152 ,  A61K31/4164 ,  A61K31/425 ,  A61K31/44 ,  A61K31/445 ,  A61K31/45 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K31/621 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P19/02 ,  A61P19/06 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  C07D207/416 ,  C07D211/88 ,  C07D401/04

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

公开(公告)号：PT1586322E

公开(公告)日：2008-10-27

申请号：PT05014759

申请日：1997-11-04

Applicant: CHILDRENS MEDICAL CENTER

Inventor： D AMATO ROBERT J

IPC: A61K31/454 ,  C07D491/044 ,  A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K31/185 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/196 ,  A61K31/20 ,  A61K31/395 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/405 ,  A61K31/4152 ,  A61K31/4164 ,  A61K31/425 ,  A61K31/44 ,  A61K31/445 ,  A61K31/45 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K31/621 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P19/02 ,  A61P19/06 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  C07D207/416 ,  C07D211/88 ,  C07D401/04

公开(公告)号：DE69738935D1

公开(公告)日：2008-10-02

申请号：DE69738935

申请日：1997-11-04

Applicant: CHILDRENS MEDICAL CENTER

Inventor： D AMATO ROBERT J

IPC: A61K31/44 ,  C07D491/044 ,  A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K31/185 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/196 ,  A61K31/20 ,  A61K31/395 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/405 ,  A61K31/4152 ,  A61K31/4164 ,  A61K31/425 ,  A61K31/445 ,  A61K31/45 ,  A61K31/454 ,  A61K31/47 ,  A61K31/5377 ,  A61K31/56 ,  A61K31/573 ,  A61K31/60 ,  A61K31/621 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P19/02 ,  A61P19/06 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  C07D207/416 ,  C07D211/88 ,  C07D401/04

Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.